Man Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-26,769
| Closed | -$156K | – | 2325 |
|
|
2022
Q4 | $156K | Buy |
+26,769
| New | +$141K | ﹤0.01% | 1820 |
|
|
2021
Q2 | – | Sell |
-22,225
| Closed | -$111K | – | 2140 |
|
|
2021
Q1 | $111K | Sell |
22,225
-47,789
| -68% | -$386K | ﹤0.01% | 1794 |
|
|
2020
Q4 | $885K | Sell |
70,014
-2,100
| -3% | -$23.9K | ﹤0.01% | 1441 |
|
|
2020
Q3 | $708K | Sell |
72,114
-800
| -1% | -$7.88K | ﹤0.01% | 1462 |
|
|
2020
Q2 | $725K | Sell |
72,914
-11,587
| -14% | -$111K | ﹤0.01% | 1361 |
|
|
2020
Q1 | $747K | Sell |
84,501
-3,113
| -4% | -$30.7K | ﹤0.01% | 1187 |
|
|
2019
Q4 | $808K | Sell |
87,614
-500
| -0.6% | -$3.54K | ﹤0.01% | 1527 |
|
|
2019
Q3 | $518K | Sell |
88,114
-73,020
| -45% | -$775K | ﹤0.01% | 1568 |
|
|
2019
Q2 | $1.93M | Sell |
161,134
-3,700
| -2% | -$39.8K | 0.01% | 1313 |
|
|
2019
Q1 | $1.99M | Sell |
164,834
-1,691
| -1% | -$24.9K | 0.01% | 1336 |
|
|
2018
Q4 | $2.09M | Sell |
166,525
-138,230
| -45% | -$1.91M | 0.01% | 1202 |
|
|
2018
Q3 | $4.52M | Sell |
304,755
-21,800
| -7% | -$343K | 0.02% | 1052 |
|
|
2018
Q2 | $5.5M | Sell |
326,555
-19,070
| -6% | -$370K | 0.02% | 892 |
|
|
2018
Q1 | $7.92M | Buy |
+345,625
| New | +$7.69M | 0.04% | 597 |
|
Man Group's CNCE Position: Q1 2023 in Review
Man Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 26,769 shares — an estimated $156K sold.
Man Group first reported a position in CNCE in Q1 2018 and held it in 14 quarters. The position peaked at $7.92M in Q1 2018. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Man Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Man Group sold 26,769 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $156K.
- Man Group first reported a position in Concert Pharmaceuticals, Inc. in Q1 2018 and held it in 14 quarters.
- Man Group's Concert Pharmaceuticals, Inc. position peaked at $7.92M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.